Hansa Biopharma has announced positive topline results from its European 20-HMedIdeS-19 Post Authorisation Efficacy Study (PAES) for Idefirix (imlifidase) in highly sensitised kidney transplant patients. The study met its primary objective, demonstrating a 90% 1-year graft failure-free survival rate, in line with previous phase II trial metrics and expectations.
LÄS MER
